Ana Cerdeira, PhD

Direct management of New Product Planning and Medical Affairs team for Development Assets in neurosciences (including rare diseases, such as DMD) - Leading a cross-functional team of Medical Affairs, Market Access and New Product Planning senior leaders to develop pipeline candidate strategy - Responsible for the initial launch strategy and LCM, integrating Strategic Marketing, Medical Affairs and Market Access - Responsible for the cross-functional Integrated Evidence Generation Plans for development assets - Responsible for patient advocacy group interactions and conference organisation for development assetss - Work with the external innovation group to evaluate the commercial potential and development strategy for selected external opportunities

Leading a cross functional team to develop an ophthalmology medicine through Phase 3 stage and registration

Advisor to the Board Implemented and led the company Portfolio Management, the New Product Planning and the Strategic Planning functions, enabling project and pipeline prioritization and resource allocation optimization. Implemented the New Product Planning function to articulate the commercial voice to support company in R&D investment decision by working cross-functionally to define the unmet needs, target profile, market potential, competitive landscape and commercial risks (including access and pricing) associated with pipeline assets Responsible for the yearly long-range forecasting and company valuation together with the CFO Ad-interim responsibility for Partnering and Alliances

Led a multi-disciplinary project team responsible to define the strategy for an early development candidate targeting the tumor microenvironment.

Reporting to the President of the Business Unit of Emerging Markets. Expert in planning, designing, and developing portfolio strategy to achieve profitable and sustainable business growth. I maintained full accountability for the new product planning, launch readiness, defining pricing and ensure market access, and marketing regional brand support for speciality care products in oncology and gastroenterology

I designed and led the Takeda global established products team. In this function I was accountable for the maintenance, issue resolution, proactive risk-assessment and strategic initiatives across the established products portfolio, including exploring inorganic and organic growth opportunities and portfolio optimization activities.

Led search and due diligence of licensing and M&A projects fitting Takeda’s commercial and early stage strategy. Project Leader of cross-functional (CMC and Supply Chain Operations, Regulatory, Commercial, Pricing and Market Access, Finance, Tax, Legal, IP and Compliance) due Diligence licensing and M&A teams I completed the acquisition of a product portfolio, a product in-licensing and gained approval from Takeda Governance bodies of the process for commercial in-licensing and Acquisitions.

I directed global multi-disciplinary teams to perform a variety of operations, including product development, clinical supply manufacturing, technical transfer to commercial operations, process validation, and launch of combination products for biologics.

Responsible for technical project leaders. Avoided stock-outs and protected value for local operating companies resulting in saved sales loss for the company in Europe > $500M, keeping high patient value products on the market protecting Janssen’s reputation and patient access to medicines. Completed the divestment and closure of the formulation technology center for Marketed Products in Switzerland.